Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Clinical Trial
Official title:
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
The Phase 1 portion of the study will determine the maximum tolerated dose of MB-102. The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05645744 -
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
|
||
| Completed |
NCT02113982 -
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04013685 -
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03599960 -
Combination Chemotherapy in Patients With Newly Diagnosed BPDCN
|
Phase 2 | |
| Terminated |
NCT03203369 -
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
|
Phase 1 | |
| Recruiting |
NCT05430971 -
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
|
||
| Recruiting |
NCT04230265 -
Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies
|
Phase 1 | |
| Recruiting |
NCT06006403 -
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
|
Phase 1/Phase 2 |